Summary
This consolidated opinion addresses cross-motions for summary judgment in John J. Frazer's Bivens claims against federal medical personnel and Federal Tort Claims Act negligence claims against the United States. The claims arise from alleged deviations between prescribed sliding-scale insulin doses, medication administration records, and the doses allegedly administered at a federal medical facility. The court considers factual disputes concerning the insulin records and administration, causation and medical harm, expert testimony, and the applicable standards for the Bivens and FTCA claims.
Topics
Practice areas
Questions Presented
- Whether Frazer was entitled to summary judgment on his FTCA medical-negligence claim when sworn declarations created a genuine dispute about the insulin doses actually administered.
- Whether Kentucky law required expert testimony to establish the standard of care, breach, injury, and proximate causation for Frazer's medical-malpractice claim under the FTCA.
- Whether res ipsa loquitur excused Frazer's failure to provide expert testimony.
- Whether Frazer was entitled to summary judgment on his Bivens Eighth Amendment claim when the record disputed the actual insulin doses administered.
- Whether a merits judgment for the United States on the FTCA claim barred the related Bivens claim under 28 U.S.C. § 2676.
Holdings
- Frazer was not entitled to summary judgment because sworn nurse declarations created a genuine dispute over whether the medication administration records accurately reflected the insulin doses actually administered.
- Frazer's FTCA medical-malpractice claim required expert testimony establishing the applicable standard of care, breach, injury, and proximate causation, and his failure to provide such testimony entitled the United States to summary judgment.
- Res ipsa loquitur did not excuse Frazer's lack of expert testimony because the disputed insulin administration and alleged hypoglycemic injuries were medically complex and not matters from which lay jurors could infer breach and causation merely from the occurrence.
- Frazer was not entitled to summary judgment on his Bivens Eighth Amendment claim because the record contained a genuine dispute about the amount of insulin the nurses actually administered.
- The merits judgment for the United States on Frazer's FTCA claim barred his related Bivens claim under 28 U.S.C. § 2676 because both claims arose from the same transactions and occurrences and involved the same precipitating employees.
Key quotations
“Second, and critically, Frazer has not supported his claim of medical malpractice with expert testimony to establish breach of the standard of care, resulting injury, or proximate cause.” (at 20)
“Because the Court has concluded that the government is entitled to summary judgment, as a matter of the merits, on Frazer’s FTCA claim and will enter judgment accordingly, Frazer’s Bivens claim arising from the same series of transactions and occurrences and against the same precipitating employees is barred by Section 2676.” (at 26)
Factual background
Frazer, a federal inmate with pancreatic diabetes and numerous other medical conditions, received insulin under a physician-prescribed sliding scale at FMC-Lexington. Medication administration records frequently reflected the maximum dose, while nurses stated that the system automatically populated that dose and that they often failed to manually correct the entries even though they administered the dose called for by Frazer's reported blood glucose level. Frazer alleged in his Bivens action that the nurses falsified records, but alleged in his FTCA action and summary-judgment motions that the records were accurate and that the nurses repeatedly overdosed him. He identified no specific severe hypoglycemic episode, lacked expert testimony on medical negligence or causation, and acknowledged substantial noncompliance with his insulin regimen.
Procedural history
Frazer filed the Bivens action in June 2023 and the FTCA action in July 2024. The cases were administratively consolidated in April 2025, with the FTCA action designated as the lead case. After briefing on cross-motions for summary judgment, the court granted defendants' motion on the FTCA claim and held that the resulting merits judgment barred the related Bivens claim under 28 U.S.C. § 2676.